Significance of Measurement of Prostate Specific Antigen (PSA) in Familial Prostate Cancer Lines.

Ohtake, Nobuaki; Nakata, Seiji; Sato, Jin; Koya, Atsushi; Saruki, Kazuhisa; Kurihara, Jun; Tsuji, Hiroaki; Imai, Kyoichi; Yamanaka, Hidetoshi; Suzuki, Keiji; Tari, K

doi:10.1620/tjem.184.21

Cited by 4 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, 69% of the patients had a family history of prostate cancer. We started to collect familial/hereditary prostate cancer pedigrees in Japan in 1994 [15,16], and we currently have about 100 pedigrees. Familial prostate cancer patients account for about 3% of all prostate cancer patients in our region.…”

Section: Discussionmentioning

confidence: 99%

A p53 Codon 72 Polymorphism Associated with Prostate Cancer Development and Progression in Japanese

et al. 2003

Self Cite

View full text Add to dashboard Cite

An association between the Pro/Pro genotype of p53 codon 72 and a lower risk of prostate cancer in Caucasians was recently reported. However, the association of this polymorphism with prostate cancer risk in a Japanese population has not been clarified. We performed a case-control study consisting of 114 prostate cancer patients and 105 noncancer controls. Sixty-nine percent (79 of 114) of the patients had a positive family history. The genotypic frequencies in the controls were 39.0% for Arg/Arg, 54.3% for Arg/Pro and 6.7% for Pro/Pro; they were in Hardy-Weinberg equilibrium. When a comparison of the distribution of the p53 codon 72 polymorphism was made between patients with a first-degree family history and all control subjects, the adjusted odds ratios (ORs) for prostate cancer associated with the Arg/Arg, Arg/Pro and Pro/Pro genotypes were 1.00, 0.99 [95% confidence interval (CI) 0.53–1.88] and 2.80 (95% CI 1.04–7.53), respectively. When stratification of cases was performed based on clinical stage (localized or metastatic cancer) and pathological grade (a Gleason score of <7 or ≧7), there tended to be a greater number of patients with localized cancers among those patients with the Arg/Pro genotype than among those with the Arg/Arg genotype (overall cases: age-adjusted OR 0.36, 95% CI 0.13–1.00, p = 0.049; positive family history cases: age-adjusted OR 0.25, 95% CI 0.075–0.84, p = 0.025). In addition, there tended to be a greater number of patients with low-grade cancers among those with the Pro/Pro genotype than among those with other genotypes (overall cases: age-adjusted OR 0.41, 95% CI 0.13–1.30, p = 0.13; positive family history cases: age-adjusted OR 0.20, 95% CI 0.004–0.89, p = 0.035). The present findings suggest that the Pro/Pro genotype of p53 codon 72 played a role in prostate cancer susceptibility in a Japanese population. However, the Pro allele did not appear to worsen such clinical parameters as clinical stage or pathological grade.

show abstract

Section: Discussionmentioning

confidence: 99%

A p53 Codon 72 Polymorphism Associated with Prostate Cancer Development and Progression in Japanese

et al. 2003

Self Cite

View full text Add to dashboard Cite

show abstract

“…We also measured PSA, in 20 asymptomatic male members (sons and brothers) of families with 2 prostate cancer patients (father, son, or brothers) per family and found 5 individuals with higher than standard levels of PSA, 3 (15%) of whom underwent prostate biopsy, and all were found to have prostate cancer. 12 In consideration of the detection rate of 1.25%-2.25% for individuals in the first periodic PSAbased screening examination for prostate cancer, 13 men with a family history of prostate cancer are at high risk of developing the disease. Thus, we recommend that, for men with a family history of prostate cancer, aggressive early screening is conducted, including PSA determination, to detect prostate cancer (we recommended screening at 40 and 50 years of age for patients with or without a family history, respectively 12,14 ).…”

Section: Discussionmentioning

confidence: 99%

Two pedigrees of hereditary prostate cancer

Nakata

Sato

Suzuki

et al. 2002

International Journal of Clinical Oncology

View full text Add to dashboard Cite

We encountered two pedigrees of hereditary prostate cancer. In one family, the father and his two sons had prostate cancer, and in the other family, three brothers developed prostate cancer. The mean age of these six individuals at the first examination was 65.3 years. Two individuals had stage B disease; three individuals, stage D disease; and one individual, disease of unknown stage. Histopathologically, two, one, and three individuals had well-, moderately, and poorly differentiated adenocarcinoma, respectively. As of September 28,2000, five of the six individuals were still alive. In a search of the literature, these were found to be the seventh and eighth pedigrees in Japan that met the criteria of hereditary prostate cancer proposed by Carter and colleagues in 1993.

show abstract

A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese

et al. 2003

View full text Add to dashboard Cite

An association between the Pro/Pro genotype of p53 codon 72 and a lower risk of prostate cancer in Caucasians was recently reported. However, the association of this polymorphism with prostate cancer risk in a Japanese population has not been clarified. We performed a case-control study consisting of 114 prostate cancer patients and 105 noncancer controls. Sixty-nine percent (79 of 114) of the patients had a positive family history. The genotypic frequencies in the controls were 39.0% for Arg/Arg, 54.3% for Arg/Pro and 6.7% for Pro/Pro; they were in Hardy-Weinberg equilibrium. When a comparison of the distribution of the p53 codon 72 polymorphism was made between patients with a first-degree family history and all control subjects, the adjusted odds ratios (ORs) for prostate cancer associated with the Arg/Arg, Arg/Pro and Pro/Pro genotypes were 1.00, 0.99 [95% confidence interval (CI) 0.53-1.88] and 2.80 (95% CI 1.04-7.53), respectively. When stratification of cases was performed based on clinical stage (localized or metastatic cancer) and pathological grade (a Gleason score of <7 or > or =7), there tended to be a greater number of patients with localized cancers among those patients with the Arg/Pro genotype than among those with the Arg/Arg genotype (overall cases: age-adjusted OR 0.36, 95% CI 0.13-1.00, p = 0.049; positive family history cases: age-adjusted OR 0.25, 95% CI 0.075-0.84, p = 0.025). In addition, there tended to be a greater number of patients with low-grade cancers among those with the Pro/Pro genotype than among those with other genotypes (overall cases: age-adjusted OR 0.41, 95% CI 0.13-1.30, p = 0.13; positive family history cases: age-adjusted OR 0.20, 95% CI 0.004-0.89, p = 0.035). The present findings suggest that the Pro/Pro genotype of p53 codon 72 played a role in prostate cancer susceptibility in a Japanese population. However, the Pro allele did not appear to worsen such clinical parameters as clinical stage or pathological grade.

show abstract

Significance of Measurement of Prostate Specific Antigen (PSA) in Familial Prostate Cancer Lines.

Cited by 4 publications

References 24 publications

A p53 Codon 72 Polymorphism Associated with Prostate Cancer Development and Progression in Japanese

A p53 Codon 72 Polymorphism Associated with Prostate Cancer Development and Progression in Japanese

Two pedigrees of hereditary prostate cancer

A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese

Contact Info

Product

Resources

About